Navigation Links
PET scans help identify mechanism underlying seasonal mood changes
Date:9/1/2008

Brain scans taken at different times of year suggest that the actions of the serotonin transporterinvolved in regulating the mood-altering neurotransmitter serotoninvary by season, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals. These fluctuations may potentially explain seasonal affective disorder and related mood changes.

"It is a common experience in temperate zones that individuals feel happier and more energetic on bright and sunny days and many experience a decline in mood and energy during the dark winter season," the authors write as background information in the article. This is thought to be related to variations in brain levels of serotonin, which is involved in the regulation of functions such as mating, feeding, energy balance and sleep. The serotonin transporter, a protein that binds to serotonin and clears it from the spaces between brain cells, "is a key element in regulating intensity and spread of the serotonin signal."

Nicole Praschak-Rieder, M.D., and Matthaeus Willeit, M.D., of the Centre for Addiction and Mental Health and the University of Toronto, Ontario, Canada, and colleagues studied 88 healthy individuals (average age 33) between 1999 and 2003. Participants underwent one positron emission tomography (PET) scan to assess serotonin transporter binding potential value, an index of serotonin transporter density. The higher the binding potential value, the less serotonin circulates in the brain. For the analysis, individual scans were grouped according to the season of the scanfall and winter or spring and summer.

"Serotonin transporter binding potential values were significantly higher in all investigated brain regions in individuals investigated in the fall and winter compared with those investigated in the spring and summer," the authors write. When they matched binding potential values to meteorological data, the researchers found that
'/>"/>

Contact: Kirk Lemessurier
416-535-8501 x6631
JAMA and Archives Journals
Source:Eurekalert

Page: 1 2

Related medicine news :

1. European directive will halt use of MRI scans; cancer diagnosis and treatment will suffer
2. PET scans can accurately detect a breast tumors response to chemotherapy
3. High-tech CT scans: not a bad choice to test for clogged arteries
4. New Computerized Scans Effective for Spotting Clogged Arteries
5. PET scans useful for some cancer treatment, but how do patients fare?
6. PET Scans Can Spot Cervical Cancers Return
7. Post-treatment PET scans can reassure cervical cancer patients
8. CT scans to determine heart disease in the emergency room
9. Obesity Keeps Patients From Needed CT Scans After Surgery
10. PET Scans Could Boost Lung Cancer Diagnosis
11. Rise in CT Scans Poses Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5FDA Launches Orphan Drug Workshop at KGI 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Researchers prolong the plasma half life of biopharmaceutical proteins 14192 1Researchers prolong the plasma half life of biopharmaceutical proteins 14192 2Pivotal Registration Trial of OPAXIO Maintenance Therapy in First Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients Cell Therapeutics 5026 1Pivotal Registration Trial of OPAXIO Maintenance Therapy in First Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients Cell Therapeutics 5026 2Pivotal Registration Trial of OPAXIO Maintenance Therapy in First Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients Cell Therapeutics 5026 3Pivotal Registration Trial of OPAXIO Maintenance Therapy in First Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients Cell Therapeutics 5026 4Fortebio Inc to Present at UBS Global Life Sciences Conference 14190 1